3 active not recruiting, 2 completed, 2 recruiting, 2 terminated. 12 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Active not recruiting 3, Completed 2, Recruiting 2, Terminated 2, Not yet recruiting 1, Suspended 1, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Gallbladder Carcinoma: new trials by email Literature Review of Gallbladder Carcinoma trials Research Report on Gallbladder Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer Daraxonrasib - Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 55 | 2026-11-01 | 2026-11-10 |
| Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide - Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 30 | 2026-03-02 | 2026-06-11 |
| Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer Trifluridine/tipiracil, Oxaliplatin - Biliary Tract Cancer, Biliary Tract Neoplasms | Phase 2 | Suspended | Case Comprehensive Cancer Center | 27 | 2025-12-01 | 2026-10-20 |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors certepetide, Durvalumab, Cisplatin - Cholangiocarcinoma, Gallbladder Cancer | Phase 2 | Completed | Lisata Therapeutics, Inc. | 66 | 2023-05-13 | 2026-09-28 |
| Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer Irinotecan Liposome Injection, SG001, Fluorouracil - Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma | Phase 2 | Terminated | CSPC Ouyi Pharmaceutical Co., Ltd. | 17 | 2021-09-01 | 2024-07-11 |
| Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers tucatinib, trastuzumab, oxaliplatin - Colorectal Carcinoma, Gastric Adenocarcinoma | Phase 2 | Active not recruiting | Seagen, a wholly owned subsidiary of Pfizer | 40 | 2020-09-15 | 2026-02-24 |
| Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA gemcitabine and oxaliplatin., Afatinib - Gallbladder Carcinoma | Phase 2 | Recruiting | Shanghai Jiao Tong University School of Medicine | 102 | 2020-06-01 | 2024-10-16 |
| Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma Apatinib, Tegafur - Gallbladder Carcinoma | Phase 2 | Unknown | Eastern Hepatobiliary Surgery Hospital | 138 | 2018-08-10 | 2018-10-11 |
| Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer Atezolizumab, Biopsy, Biospecimen Collection - Gallbladder Carcinoma, Metastatic Cholangiocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 86 | 2018-02-08 | 2024-04-05 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
| A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer Selumetinib, Cisplatin, Gemcitabine - Biliary Tract Carcinoma, Gallbladder Carcinoma | Phase 2 | Active not recruiting | University Health Network, Toronto | 57 | 2014-11-01 | 2026-06-22 |
| Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer Gemcitabine-Pazopanib - Cholangiocarcinoma, Gallbladder Carcinoma | Phase 2 | Terminated | Hellenic Cooperative Oncology Group | 29 | 2013-06-28 | 2018-11-07 |
Gallbladder Neoplasms (12) · Cholangiocarcinoma (9) · Biliary Tract Neoplasms (3) · Bile Duct Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Adenocarcinoma, Mucinous (1) · Adrenocortical Carcinoma (1) · Carcinoma (1) · Carcinoma, Acinar Cell (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Basal Cell (1) · Carcinoma, Endometrioid (1) · Carcinoma, Giant Cell (1) · Carcinoma, Transitional Cell (1)
Biliary Tract Diseases (12) · Digestive System Diseases (12) · Digestive System Neoplasms (12) · Gallbladder Diseases (12) · Neoplasms (12) · Neoplasms by Site (12) · Adenocarcinoma (9) · Biliary Tract Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms, Glandular and Epithelial (9) · Carcinoma (8) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Disease Attributes (3) · Gastrointestinal Diseases (3)
Oxaliplatin (5) · Gemcitabine (4) · Fluorouracil (3) · Leucovorin (3) · Cisplatin (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · AZD 6244 (1) · Afatinib (1) · Biopsy (1) · CTLA-4 Antigen (1) · Capecitabine (1) · Commerce (1) · Cyclophosphamide (1) · Folfox protocol (1)
National Cancer Institute (NCI) (2) · Beijing Biotech (1) · CSPC Ouyi Pharmaceutical Co., Ltd. (1) · Case Comprehensive Cancer Center (1) · Eastern Hepatobiliary Surgery Hospital (1) · Hellenic Cooperative Oncology Group (1) · Lisata Therapeutics, Inc. (1) · Seagen, a wholly owned subsidiary of Pfizer (1) · Shanghai Jiao Tong University School of Medicine (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University Health Network, Toronto (1)
United States (6) · China (4) · Canada (1) · Greece (1) · Guam (1) · Japan (1)
Jennifer Knox, M.D. (1) · Joseph Sgouros, MD (1) · Kristen K Buck, MD (1) · Madison Conces, MD (1) · Nilo Azad, MD (1) · Nilofer S Azad (1) · Sandip P Patel (1) · Xiangdong Cheng (1) · Yingbin Liu, PHD (1)
PMID 31969335, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 34907910, PMID 36854604, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790
2023 (1), U10CA180888 (1), UM1CA186691 (1)